After 95 years, it's time to eRASe JMML.

Abstract excerpt

Juvenile myelomonocytic leukaemia (JMML) is a rare clonal disorder of early childhood. Constitutive activation of the RAS pathway is the initial event in JMML. Around 90% of patients diagnosed with JMML carry a mutation in the PTPN11, NRAS, KRAS, NF1 or CBL genes. It has been demonstrated that after this first genetic event, an additional somatic mutation or epigenetic modification is involved in disease...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Epigenesis, Genetic
• Share to Gene Expression Regulation, Leukemic
• Share to GTP Phosphohydrolases